Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MLN2704
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MLN2704 is an investigational antibody-drug conjugate (ADC) developed for the treatment of metastatic castration-resistant prostate cancer. It consists of a humanized monoclonal antibody (MLN591) that targets prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells, conjugated via a disulfide linker to the cytotoxic maytansinoid DM1, a potent microtubule inhibitor. Upon binding to PSMA-expressing tumor cells, MLN2704 is internalized and releases DM1 inside the cell, where it binds to tubulin and disrupts microtubule assembly, leading to cell death. Clinical trials showed limited efficacy and significant neurotoxicity due to instability of the linker and rapid deconjugation of DM1 from the antibody[1][2][4][5][6].
- Other names
- anti-PSMA monoclonal antibody MLN591-DM1 immunoconjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on MLN2704.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MLN2704.